![Transparency Market Researchが調査・発行した産業分析レポートです。小細胞肺がん（SCLC）治療薬のグローバル市場（2022年-2031年）：化学療法、標的療法、免疫療法、その他 / Small Cell Lung Cancer [SCLC] Therapeutics Market (Therapy Type: Chemotherapy, Targeted Therapy, Immunotherapy, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031 / MRC2304D147資料のイメージです。](https://www.marketresearch.co.jp/images-folder2/99x123xreport-contents-86.gif.pagespeed.ic.cYgo-ZH9PJ.jpg) | • レポートコード：MRC2304D147 • 出版社/出版日：Transparency Market Research / 2023年1月24日 • レポート形態：英文、PDF、160ページ • 納品方法：Eメール • 産業分類：医薬品 |
| Single User | ￥869,250 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,319,250 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,769,250 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の当調査レポートでは、小細胞肺がん（SCLC）治療薬の世界市場を分析し、市場実態を明らかにしています。本書は、序論、仮定＆調査手法、エグゼクティブサマリー、市場概要、キーインサイト、治療種類別（化学療法、標的療法、免疫療法、その他）分析、エンドユーザー別（病院、がん治療センター、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などを収録しています。また、ZIOPHARM Oncology、GlaxoSmithKline、Menarini、Bristol-Myers Squibb、Sanofi、Novartis AG、Elekta AB、Siemens Healthcare GmbH、G1 Therapeuticsなどの企業情報を掲載しています。 ・序論 ・仮定＆調査手法 ・エグゼクティブサマリー ・市場概要 ・キーインサイト ・世界の小細胞肺がん（SCLC）治療薬市場規模：治療種類別 - 化学療法の市場規模 - 標的療法の市場規模 - 免疫療法の市場規模 - その他治療種類の市場規模 ・世界の小細胞肺がん（SCLC）治療薬市場規模：エンドユーザー別 - 病院における市場規模 - がん治療センタにおける市場規模 - その他エンドユーザーにおける市場規模 ・世界の小細胞肺がん（SCLC）治療薬市場規模：地域別 - 北米の小細胞肺がん（SCLC）治療薬市場規模 - ヨーロッパの小細胞肺がん（SCLC）治療薬市場規模 - アジア太平洋の小細胞肺がん（SCLC）治療薬市場規模 - 中南米のアルミニウムスラグ市場規模 - 中東・アフリカのアルミニウムスラグ市場規模 ・競争状況 |
Small Cell Lung Cancer [SCLC] Therapeutics Market – Scope of Report
TMR’s report on the global small cell lung cancer [SCLC] therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global small cell lung cancer [SCLC] therapeutics market for the period 2017–2031, considering 2022 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global small cell lung cancer [SCLC] therapeutics market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the small cell lung cancer [SCLC] therapeutics market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global small cell lung cancer [SCLC] therapeutics market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global small cell lung cancer [SCLC] therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global small cell lung cancer [SCLC] therapeutics market.
The report delves into the competitive landscape of the global small cell lung cancer [SCLC] therapeutics market. Key players operating in the global small cell lung cancer [SCLC] therapeutics market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global small cell lung cancer [SCLC] therapeutics market profiled in this report.
RESEARCH METHODOLOGY
The research methodology will be a combination of exhaustive primary and secondary research to analyze the market small cell lung cancer [SCLC] therapeutics.
Secondary Research
Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.
Secondary research sources that we typically refer, but are not limited to:
Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market
Specific Secondary Sources:
• Industry Sources:
o WorldWideScience.org
o Elsevier, Inc.
o National Institutes of Health (NIH)
o PubMed
o NCBI
o Department of Health Care Service
• Trade Data Sources
o Trade Map
o UN Comtrade
o Trade Atlas
• Company Information
o OneSource Business Browser
o Hoover’s
o Factiva
o Bloomberg
• Mergers & Acquisitions
o Thomson Mergers & Acquisitions
o MergerStat
o Profound
Primary Research
During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.
We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:
Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies
Participants who typically take part in such a process include, but are not limited to:
Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals
List of primary participants, but not limited to:
Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.
Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.
Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:
Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Small Cell Lung Cancer (SCLC) Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Technological Advancements
5.2. Pipeline Analysis
5.3. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)
6. Global Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast, by Therapy Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Therapy Type, 2017–2031
6.3.1. Chemotherapy
6.3.2. Targeted Therapy
6.3.3. Immunotherapy
6.3.4. Others
6.4. Market Attractiveness Analysis, by Therapy Type
7. Global Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast, by End-user
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by End-user, 2017–2031
7.3.1. Hospitals
7.3.2. Cancer Therapy Centers
7.3.3. Others (Specialty Clinics)
7.4. Market Attractiveness Analysis, by End-user
8. Global Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Region
9. North America Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Therapy Type, 2017–2031
9.2.1. Chemotherapy
9.2.2. Targeted Therapy
9.2.3. Immunotherapy
9.2.4. Others
9.3. Market Value Forecast, by End-user, 2017–2031
9.3.1. Hospitals
9.3.2. Cancer Therapy Centers
9.3.3. Others (Specialty Clinics)
9.4. Market Value Forecast, by Country, 2017–2031
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Therapy Type
9.5.2. By End-user
9.5.3. By Country
10. Europe Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Therapy Type, 2017–2031
10.2.1. Chemotherapy
10.2.2. Targeted Therapy
10.2.3. Immunotherapy
10.2.4. Others
10.3. Market Value Forecast, by End-user, 2017–2031
10.3.1. Hospitals
10.3.2. Cancer Therapy Centers
10.3.3. Others (Specialty Clinics)
10.4. Market Value Forecast, by Country/Sub-region, 2017–2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Therapy Type
10.5.2. By End-user
10.5.3. By Country/Sub-region
11. Asia Pacific Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Therapy Type, 2017–2031
11.2.1. Chemotherapy
11.2.2. Targeted Therapy
11.2.3. Immunotherapy
11.2.4. Others
11.3. Market Value Forecast, by End-user, 2017–2031
11.3.1. Hospitals
11.3.2. Cancer Therapy Centers
11.3.3. Others (Specialty Clinics)
11.4. Market Value Forecast, by Country/Sub-region, 2017–2031
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Therapy Type
11.5.2. By End-user
11.5.3. By Country/Sub-region
12. Latin America Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Therapy Type, 2017–2031
12.2.1. Chemotherapy
12.2.2. Targeted Therapy
12.2.3. Immunotherapy
12.2.4. Others
12.3. Market Value Forecast, by End-user, 2017–2031
12.3.1. Hospitals
12.3.2. Cancer Therapy Centers
12.3.3. Others (Specialty Clinics)
12.4. Market Value Forecast, by Country/Sub-region, 2017–2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Therapy Type
12.5.2. By End-user
12.5.3. By Country/Sub-region
13. Middle East & Africa Small Cell Lung Cancer (SCLC) Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Therapy Type, 2017–2031
13.2.1. Chemotherapy
13.2.2. Targeted Therapy
13.2.3. Immunotherapy
13.2.4. Others
13.3. Market Value Forecast, by End-user, 2017–2031
13.3.1. Hospitals
13.3.2. Cancer Therapy Centers
13.3.3. Others (Specialty Clinics)
13.4. Market Value Forecast, by Country/Sub-region, 2017–2031
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Therapy Type
13.5.2. By End-user
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player – Competition Matrix (by tier and size of companies)
14.2. Market Share Analysis, by Company (2021)
14.3. Company Profiles
14.3.1. ZIOPHARM Oncology
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Product Portfolio
14.3.1.3. Financial Overview
14.3.1.4. SWOT Analysis
14.3.1.5. Strategic Overview
14.3.2. GlaxoSmithKline
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Product Portfolio
14.3.2.3. Financial Overview
14.3.2.4. SWOT Analysis
14.3.2.5. Strategic Overview
14.3.3. Menarini
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Product Portfolio
14.3.3.3. Financial Overview
14.3.3.4. SWOT Analysis
14.3.3.5. Strategic Overview
14.3.4. Bristol-Myers Squibb
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Product Portfolio
14.3.4.3. Financial Overview
14.3.4.4. SWOT Analysis
14.3.4.5. Strategic Overview
14.3.5. Sanofi
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Product Portfolio
14.3.5.3. Financial Overview
14.3.5.4. SWOT Analysis
14.3.6. Novartis AG
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Product Portfolio
14.3.6.3. Financial Overview
14.3.6.4. SWOT Analysis
14.3.7. Elekta AB
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Product Portfolio
14.3.7.3. Financial Overview
14.3.7.4. SWOT Analysis
14.3.8. Siemens Healthcare GmbH
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Product Portfolio
14.3.8.3. Financial Overview
14.3.8.4. SWOT Analysis
14.3.9. G1 Therapeutics
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Product Portfolio
14.3.9.3. Financial Overview
14.3.9.4. SWOT Analysis